Israel · Delayed Price · Currency is ILS · Price in ILA Can-Fite BioPharma Earnings Call Transcripts
Fiscal Year 2024
-
Multiple late-stage clinical programs are advancing, including pivotal phase III trials for psoriasis and liver cancer, and a new phase IIa trial in pancreatic cancer. Strategic partnerships and licensing deals have generated significant revenue, with strong market opportunities ahead.
-
Recent fundraising and milestone payments provide 16-18 months of runway, with additional non-dilutive funding expected from partnerships. Key clinical catalysts include pivotal phase III studies in psoriasis and liver cancer, and phase IIb in MASH, with interim data due next year.
-
Multiple late-stage clinical programs are advancing, with pivotal studies in liver cancer and psoriasis set to begin. $20 million has been secured from licensing, with potential for $130 million more, targeting multi-billion-dollar markets and further milestones in 2024.
-
Two lead drug candidates are advancing through pivotal phase III trials for psoriasis and liver cancer, with additional indications in development and strong safety profiles. Multiple licensing deals and a solid cash position support ongoing operations, while analyst coverage and orphan drug status enhance the company's outlook.
-
Two pivotal phase III trials are underway for psoriasis and liver cancer, with interim analyses planned that could enable conditional approval. Multiple out-licensing deals and a strong cash position support ongoing development, while new partnerships and non-dilutive funding are being pursued.